TY - JOUR T1 - Lung Cancer, Covid-19 Infections and Chemotherapy JF - In Vivo JO - In Vivo SP - 1877 LP - 1880 DO - 10.21873/invivo.12450 VL - 35 IS - 3 AU - BOGDAN HAINEALA AU - ANCA ZGURA AU - DUMITRU CRISTINEL BADIU AU - LAURA ILIESCU AU - RODICA MARICELA ANGHEL AU - XENIA ELENA BACINSCHI Y1 - 2021/05/01 UR - http://iv.iiarjournals.org/content/35/3/1877.abstract N2 - Background/Aim: The Covid-19 epidemic has severely strained health care systems across the globe. The impacts are multiple especially for patients cared for cancer. The Covid-19 epidemic has several impacts on the management of lung cancer patients. The aim of this work was to summarize the available epidemiological data on patients diagnosed with lung cancer infected with Covid-19 and describe the different strategies to improve the management of these patients by summarizing the recommendations in this area. Patients and Methods: The Teravolt cohort is an observational multicenter registry, including patients with non-small cell cancer, small cell cancer or mesothelioma but also epithelial tumors and a diagnosis of Covid-19. The Theravolt registry indicates an unexpectedly high mortality rate in patients with thoracic malignancies with COVID-19. Results: Between March 26 and April 12, 2020, 200 patients treated in 8 countries were included. They had a performance status (PS) of 0-1 in 72% of cases, were smokers or ex-smokers in 81% of cases, had non-small cell cancer (76% of cases), were under treatment in 74% of cases, and the majority were first-line cases (57%). The hospitalization rate was 76% and the mortality rate 33%; only 10% of patients with criteria for intensive care hospitalization were admitted to the intensive care. Conclusion: Data presented in this registry suggest a high mortality in patients with thoracic cancer and Covid-19. Therofere, the importance to create a safe healthcare system during Covid-19 pandemic is underlined along with the need for essential effective clinical service delivery to patients with lung cancer. ER -